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ABSTRACT
Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor 
in adults. With a median patient survival of less than two years, GBM represents one 
of the biggest therapeutic challenges of the modern era. Even with the best available 
treatment, recurrence rates are nearly 100% and therapeutic options at the time 
of relapse are extremely limited. Nivolumab, an anti-programmed cell death-1 (PD-
1) monoclonal antibody, has provided significant clinical benefits in the treatment 
of various advanced cancers and represented a promising therapy for primary and 
recurrent GBM. CheckMate 143 (NCT 02017717) was the first large randomized 
clinical trial of PD pathway inhibition in the setting of GBM, including a comparison 
of nivolumab and the anti-VEGF antibody, bevacizumab, in the treatment of recurrent 
disease. However, preliminary results, recently announced in a WFNOS 2017 abstract, 
demonstrated a failure of nivolumab to prolong overall survival of patients with 
recurrent GBM, and this arm of the trial was prematurely closed. In this review, we 
discuss the basic concepts underlying the rational to target PD pathway in GBM, 
address implications of using immune checkpoint inhibitors in central nervous system 
malignancies, provide a rationale for possible reasons contributing to the failure of 
nivolumab to prolong survival in patients with recurrent disease, and analyze the 
future role of immune checkpoint inhibitors in the treatment of GBM.
INTRODUCTION
Glioblastoma (GBM) is the most commonly 
diagnosed primary brain tumor in adults. These tumors 
are highly aggressive and the prognosis for patients is 
extremely poor, with median overall survival of 14.6 
months and 5-year survival rates less than 10% following 
standard of care treatment [1, 2]. With near 100% 
relapse rates and limited treatment options at the time of 
recurrence, GBM represents one of the biggest therapeutic 
challenges of our time.
The development of effective treatments for GBM, 
both primary and recurrent, has been challenged by the 
intracranial location and infiltrative growth of these 
tumors, extensive molecular heterogeneity, and associated 
immunosuppression. Although surgery is a key component 
of the standard treatment, in many cases complete or 
even partial resection is deemed unattainable due to the 
eloquent nature of the involving brain tissue. Furthermore, 
despite maximal surgical resection, the highly infiltrative 
nature of GBM ensures local recurrence, in contrast to 
the metastatic nature of other aggressive tumors. Tumors 
are further protected by the blood brain barrier (BBB), a 
semipermeable membrane of endothelial cells connected 
by tight junctions, which prevents the passage of most 
conventional drugs to tumor sites [3, 4]. A hallmark 
adaptation of GBM is the development of a profoundly 
immunosuppressive tumor microenvironment (TME) that 
cripples endogenous antitumor immune responses and 
limits the effectiveness of immunotherapies [5, 6].
The programmed cell death (PD) pathway is an 
endogenous negative feedback mechanism for T-cell 
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activity that is often exploited by human tumors, 
including GBM, to suppress the antitumor efficacy of 
incoming CD8+ cytotoxic T lymphocytes (CTLs) [7, 
8]. Immune checkpoint inhibition with monoclonal 
antibodies targeting the programmed cell death-1 (PD-
1) protein or its ligand, PD-L1, has produced significant 
clinical results in the treatment of several cancers, most 
notably metastatic melanoma [9, 10] and non-small cell 
lung cancer (NSCLC) [11, 12], and has shown promise 
in preclinical studies for the treatment of GBM [13, 14]. 
CheckMate 143 (NCT02017717) was the first randomized 
phase III clinical trial of PD pathway inhibition in the 
setting of GBM, including a comparison of nivolumab 
(Opdivo) and the anti-vascular endothelial growth factor 
(VEGF) antibody, bevacizumab (Avastin), in the treatment 
of recurrent GBM. Early results presented at WFNOS 
conference 2017 revealed that nivolumab did not prolong 
overall survival (OS) in these patients, the primary 
endpoint of the study, and consequently this arm of the 
trial was closed [15].
Although this failure can be regarded as a setback, 
it provides an opportunity to reevaluate existing 
treatment strategies, spurring research that will improve 
our understanding of GBM, ultimately leading to the 
development of more effective therapies for patients 
with this devastating illness. A thorough analysis of the 
CheckMate 143 trial and factors potentially contributing to 
its failure is imperative in accomplishing this goal. In this 
review we discuss the basic science concepts underlying 
the rationale to target PD-1 pathway in GBM.
CLINICAL MANAGEMENT OF GBM
The current standard of care for newly diagnosed 
GBM is maximal surgical resection and concurrent 
radiotherapy (RT) and temozolomide (TMZ) 
chemotherapy, followed by 6 months of adjuvant TMZ 
[1]. A recent phase III trial evaluating the addition of 
tumor treating fields (TTFs) to the TMZ and radiation 
protocol showed increased OS from 16 months to 21 
months in newly diagnosed GBM [16]. However, even 
with the best available treatment, GBM has a near 
100% relapse rate with a median time to recurrence of 
7 months [2]. Treatment options at this time are limited; 
repeat surgery is considered for approximately 25% of 
patients and re-irradiation is only possible as a palliative 
option in rare cases [17]. Chemotherapy response rates, 
including to TMZ, typically do not exceed 10% and none 
have been shown to prolong OS [18–22]. Although two 
large randomized trials failed to show increased OS with 
addition of bevacizumab, an anti-VEGF monoclonal 
antibody, to the current treatment strategy [23, 24], it is 
regularly used in the treatment of recurrent GBM due 
to a demonstrated ability to prolong progression-free 
survival (PFS), reduce the use of immunosuppressive 
corticosteroids, and improve patient quality of life, both 
as a monotherapy and in combination with other cytotoxic 
agents [25–28]. Overall, the median survival for patients 
with recurrent disease typically ranges between 6.6 
and 9.6 months, with one recent study showing overall 
survival rates of slightly over one year for patients treated 
with TTFs [29].
GBM AND IMMUNOTHERAPY
The field of immunotherapy centers on the natural 
ability of the host immune system to identify and destroy 
malignant cells, an ability that is often impaired in the 
setting of cancer, particularly GBM [6]. Immunotherapies 
are targeted towards activating and enhancing endogenous 
host immune responses. Among those being investigated 
are: 1) T-cell based therapies like chimeric antigen 
receptor (CAR) T-cells and adoptive transfer of immune 
cells to directly bolster antitumor immunity, 2) therapeutic 
vaccines that enhance antigen presentation and stimulate 
the generation of robust antitumor immune responses, 3) 
viruses engineered to selectively infect and destroy tumor 
cells, and 4) antibody inhibition of signaling through 
tumor-promoting pathways (VEGF, CTLA-4, PD-1 etc.) 
(Figure 1).
ENDOGENOUS PD PATHWAY
The PD pathway is an endogenous negative 
feedback mechanism for T-cell activity that functions 
in the healthy host to minimize tissue damage incurred 
with prolonged inflammatory responses and prevent the 
development of autoimmunity by inducing peripheral 
tolerance to self-antigens [7, 30]. An overview of the 
endogenous PD pathway is shown in Figure 2.
PD PATHWAY IN CANCER
Seldom present on healthy cells in the steady state, 
PD-L1 is often expressed by both tumor cells and tumor-
infiltrating lymphocytes (TILs) in a variety of human 
cancers, including GBM [31–34]. In a recent study of 
human GBM, 88% of tumors expressed PD-L1 [31], 
further supporting an exploration of the role of the PD 
pathway in malignant glioma. Induction of tumor PD-
L1 expression likely occurs in response to inflammation 
induced by host antitumor immune responses [34] and 
through tumor-specific mutations, such as loss of the 
tumor-suppressor PTEN or enhanced ALK gene signaling 
[35, 36]. An overview of the PD-1 pathway in cancer is 
shown in Figure 3.
PD signaling in the setting of cancer represents an 
adaptation through which tumors can exploit endogenous 
cellular feedback mechanisms to suppress antitumor 
immune responses in a mechanism termed “adaptive 
resistance” [7]. Tumor PD-L1 binds to PD-1 receptors 
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Figure 2: PD-1 is constitutively expressed on activated T cells, B cells, and other myeloid cells.  Release of IFN-γ by 
activated T lymphocytes during inflammatory responses directly induces local PD-L1 expression on surrounding cells. Binding of PD-L1 
to lymphocyte-expressed PD-1 transmits an inhibitory feedback signal that suppresses T cell proliferation and cytokine release and induces 
T cell anergy, apoptosis, and the development of regulatory T cells, thereby attenuating inflammatory responses.
Figure 1: Commonly employed immunotherapeutic strategies enhance antitumor immunity by addressing different 
components of the immune response.  1) Antitumor immunity can be directly bolstered with the adoptive transfer of specialized and 
functional T cells. 2) Therapeutic vaccines that enhance dendritic cell function and presentation of tumor antigens promote more efficient 
activation of antigen specific CD8+ T cell responses. 3) Oncolytic viruses can selectively infect and lyse tumor cells, releasing tumor 
associated antigens into the glioma microenvironment which can be taken up by the resident DCs. 4) Monoclonal antibodies targeting 
immune cell (ex. CTLA-4, PD-1) and tumor-expressed (PD-L1, VEGF) molecules can be used to inhibit signaling through pathways that 
promote tumor cell growth or inhibit immune cell responses.
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on infiltrating effector T-cells, inhibiting their cytotoxic 
activity and thereby rendering malignant cells resistant 
to CTL-mediated destruction [37]. Elevated tumor PD-
L1 expression has been associated with aggressive 
disease and poor prognoses in several cancers including 
renal [38], pancreatic [34], breast [32], ovarian [39], 
esophageal [40], and gastric cancers [41]. Patients with 
PD-L1-positive tumors displayed local evidence of 
impaired cellular immune responses, including a paucity 
of TILs or an abundance of heavily immunosuppressed 
and dysfunctional effector cells [34, 39]. However, in 
other studies of NSCLC [42], colorectal cancer [33], and 
melanoma [43], tumor PD-L1 expression was associated 
with evidence of strong ongoing antitumor immune 
responses and correlated with a positive prognosis. 
These patients seem to be benefitting from robust 
inflammatory antitumor responses that, in turn, induce 
PD-L1 expression. Furthermore, in some of these cases, 
infiltrating effector cells lacked PD-1 expression entirely, 
rendering them functionally insensitive to PD-L1-
mediated inhibition [33].
With respect to GBM, although the 
immunosuppressive effects of the PD pathway have 
been well documented in preclinical studies, the overall 
relationship between baseline tumor PD-L1 expression 
and patient prognosis remains unclear. Several studies 
have correlated elevated pretreatment levels of PD-L1 
with a worse prognosis [44, 45], whereas others have 
found no prognostic predictive value [31].
CLINICALLY TARGETING PD PATHWAY 
IN CANCER
Given the observed role of the PD-1/PD-L1 immune 
checkpoint in the pathophysiology of tumor-induced 
immunosuppression, blockade of these interactions 
represents a promising anticancer treatment strategy. 
Human ex vivo studies have demonstrated reversal of PD 
pathway-mediated T-cell exhaustion and enhancement 
of lymphocyte proliferation and cytokine production 
after administration of monoclonal antibodies targeting 
either PD-1 or PD-L1 [46–51]. Preclinical studies 
in mouse tumor models have established the in vivo 
safety and efficacy of these agents, yielding significant 
tumor regression and prolonged animal survival in the 
setting of many cancers, including GBM [14, 52, 53]. 
In phase III clinical trials, anti-PD pathway therapies 
have produced substantial clinical responses in a subset 
of patients with variety of cancers [9–12, 54–56], 
culminating in FDA approval of two immune checkpoint 
inhibitors, pembrolizumab and nivolumab, both anti-PD-1 
monoclonal antibodies, in the treatment of unresectable or 
metastatic melanoma (pembrolizumab and nivolumab) and 
NSCLC (nivolumab) [57, 58]. A list of all currently active 
clinical trials of PD-1/PD-L1 inhibitors in patients with 
malignant glioma is shown in Table 1  [59–68].
Given that the checkpoint inhibitors exert their 
antitumor effects by preventing PD-1/PD-L1 interactions 
Figure 3: In the setting of cancer, PD-L1 is upregulated on tumor cells in response to IFN-γ released by infiltrating 
immune cells during antitumor immune responses, as well as through tumor-specific IFN-γ-independent mechanisms. 
PD-L1 serves as a receptor on cancer cells that, through interactions with PD-1expressing TIL, induces an intrinsic resistance to CTL killing 
and suppresses antitumor immune responses.
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Table 1: Clinical trials with PD-1/PD-L1 blockade in malignant glioma
Malignancy Phase N Name of trial Therapeutic compounds
Clinical trial 
identifier Status References
Recurrent 
High Grade 
Glioma
I 26*
Hypofractionated 
Stereotactic 
Irradiation With 
Nivolumab in Patients 
With Recurrent High 
Grade Gliomas
Nivolumab, 
hfSRT NCT02829931 Recruiting [59]
Recurrent 
Malignant 
Glioma
I 46*
Hypofractionated 
Stereotactic 
Irradiation (HFSRT) 
With Pembrolizumab 
and Bevacizumab for 
Recurrent High Grade 
Gliomas
Pembrolizumab, 
bevacizumab, 
hfSRT
NCT02313272 Recruiting [60, 61]
Malignant 
Glioma I 66
*
Nivolumab With 
DC Vaccines for 
Recurrent Brain 
Tumors (AVERT)
Nivolumab, DC 
vaccine NCT02529072 Recruiting
Glioblastoma, 
Gliosarcoma II 48
*
Combination 
Adenovirus + 
Pembrolizumab to 
Trigger Immune Virus 
Effects (CAPTIVE)
DNX-2401, 
pembrolizumab NCT02798406 Recruiting
Glioblastoma I/II 60*
A Phase 1/2 
Safety Study of 
Intratumorally Dosed 
INT230-6 (IT-01)
INT230-6, anti-
PD-1 antibody NCT03058289 Recruiting
Glioblastoma II 205*
A Dose Escalation 
and Cohort Expansion 
Study of Anti-CD27 
(Varlilumab) and Anti-
PD-1 (Nivolumab) in 
Advanced Refractory 
Solid Tumors
Varlilumab, 
nivolumab NCT02335918 Recruiting [62]
Recurrent/
Progressive 
Glioblastoma
Pilot 30*
A Pilot Surgical 
Trial To Evaluate 
Early Immunologic 
Pharmacodynamic 
Parameters 
For The PD-1 
Checkpoint Inhibitor, 
Pembrolizumab 
(MK-3475), In 
Patients With 
Surgically Accessible 
Recurrent/Progressive 
Glioblastoma
Pembrolizumab NCT02852655 Recruiting
(Continued )
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Malignancy Phase N Name of trial Therapeutic compounds
Clinical trial 
identifier Status References
Glioblastoma, 
Gliosarcoma, 
Recurrent 
Brain 
Neoplasm
I 68*
Anti-LAG-3 or 
Urelumab Alone 
and in Combination 
With Nivolumab in 
Treating Patients 
With Recurrent 
Glioblastoma
Anti-LAG-3, 
urelumab, 
nivolumab
NCT02658981 Recruiting
Glioblastoma, 
other select 
advance solid 
tumors
I 280*
Study of FPA008 
in Combination 
With Nivolumab in 
Patients With Selected 
Advanced Cancers 
(FPA008-003)
FPA008, 
nivolumab NCT02526017 Recruiting [63]
Glioblastoma I 6*
Intra-tumoral 
Ipilimumab Plus 
Intravenous 
Nivolumab Following 
the Resection 
of Recurrent 
Glioblastoma 
(GlitIpNi)
Ipilimumab, 
nivolumab NCT03233152 Recruiting
Glioblastoma II 43*
Avelumab With 
Hypofractionated 
Radiation Therapy in 
Adults With Isocitrate 
Dehydrogenase (IDH) 
Mutant Glioblastoma
Avelumab NCT02968940 Recruiting
Glioblastoma, 
other select 
advance solid 
tumors
I/II 291*
A Study of the 
Safety, Tolerability, 
and Efficacy 
of Epacadostat 
Administered in 
Combination With 
Nivolumab in Select 
Advanced Cancers 
(ECHO-204)
Nivolumab, 
epacadostat NCT02327078 Recruiting [64]
Malignant 
Glioma, 
Recurrent 
Glioblastoma
II 36*
Tremelimumab 
and Durvalumab in 
Combination or Alone 
in Treating Patients 
With Recurrent 
Malignant Glioma
Durvalumab, 
tremelimumab, 
surgical procedure
NCT02794883 Recruiting
Recurrent 
Malignant 
Glioma
I/II 52*
MK-3475 in 
Combination With 
MRI-guided Laser 
Ablation in Recurrent 
Malignant Gliomas
MK-3475, MRI-
guided laser 
ablation
NCT02311582 Recruiting
(Continued )
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Malignancy Phase N Name of trial Therapeutic compounds
Clinical trial 
identifier Status References
Glioblastoma 
Multiforme I 20
*
Pilot Study of 
Autologous 
Chimeric Switch 
Receptor Modified 
T Cells in Recurrent 
Glioblastoma 
Multiforme
Anti-PD-L1 
CSR T cells, 
cyclophosphamide, 
fludarabine
NCT02937844 Recruiting
Glioblastoma I/II 62*
A Study Evaluating 
the Association of 
Hypofractionated 
Stereotactic 
Radiation Therapy 
and Durvalumab 
for Patients 
With Recurrent 
Glioblastoma 
(STERIMGLI)
Durvalumab, 
hfSRT NCT02866747 Recruiting
Glioblastoma II 159
Phase 2 Study of 
MEDI4736 in Patients 
With Glioblastoma
MEDI4736, 
radiotherapy, 
bevacizumab
NCT02336165 Active, Not Recruiting [65, 66]
Recurrent 
Glioblastoma II 82
Pembrolizumab +/- 
Bevacizumab for 
Recurrent GBM
Pembrolizumab, 
bevacizumab NCT02337491
Active, Not 
Recruiting [67]
Recurrent 
Glioblastoma II 30
*
Autologous Dendritic 
Cells Pulsed With 
Tumor Lysate 
Antigen Vaccine 
and Nivolumab in 
Treating Patients 
With Recurrent 
Glioblastoma
Autologous 
DCs pulsed with 
tumor lysate 
antigen vaccine, 
nivolumab
NCT03014804 Not Yet Recruiting
Glioblastoma 
Multiforme II 29
Neoadjuvant 
Nivolumab in 
Glioblastoma (Neo-
nivo)
Nivolumab NCT02550249 Completed
Recurrent 
High-Grade 
Gliomas
20
OS09.5 Synergistic 
effect of reirradiation 
and PD-1 inhibitors in 
recurrent high-grade 
gliomas
PD-1 Inhibitors, 
reirradiation [68]
hfSRT – hypofractionated stereotactic irradiation.
* Estimated/Anticipated sample size.
thereby allowing for uninhibited effector T-cell activity, 
positive clinical responses to treatment would be expected 
to correlate with evidence of active antitumor immune 
responses. Supporting this assertion, numerous studies 
involving various cancers have associated patient response 
to treatment with the selective expansion and activation of 
antigen-specific CD8+ CTLs, reduced Treg cell activity, 
IFN-γ secretion and expression of IFN-γ-inducible 
genes, and subsequent IFN-γ-induced upregulation of 
PD-L1 expression on both tumor cells and TILs [9, 69–
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75]. Biopsies of regressing lesions demonstrate dense 
intratumoral CD8+ infiltrates [69, 73], and elevations 
in peripheral blood lymphocyte counts are observed as 
well [71, 75, 76]. Patients not responding to treatment 
characteristically have lacked this evidence of immune 
activation and possess reduced numbers of peripheral 
blood antigen-specific T-cells, instead accumulating 
immunosuppressive regulatory T-cells [77].
Immune checkpoint inhibition has been shown to be 
particularly effective in patients with elevated pretreatment 
levels of tumor PD-L1 expression [9, 11, 55, 70, 71, 74, 
77–83]. In one such study of NSCLC, treatment with the 
anti-PD-1 antibody nivolumab was shown to be more 
effective than docetaxel chemotherapy in patients with 
PD-L1 positive, but not PD-L1 negative, tumors at all 
classified levels of PD-L1 expression (≥1%, ≥5%, and 
≥10% of tumor cells) [11]. Similarly, in a phase I trial of 
nivolumab in 90 patients with unresectable melanoma, 
overall response rates were observed in 67% of patients 
with PD-L1-positive tumors (≥5%) as compared to 19% of 
patients with PD-L1-negative tumors [9]. However, even 
patients with PD-L1-negative tumors have been shown to 
receive some survival benefit from anti-PD-1 therapy [12, 
54, 56, 70]. For example, in another phase III clinical trial 
of nivolumab vs docetaxel in NSCLC patients, prolonged 
survival was seen in patients treated with nivolumab, 
regardless of tumor cell PD-L1 expression [12]. The 
possibility exists that in this and other similar cases, PD 
blockade exerts therapeutic effects, at least partially, by 
preventing TILs from interacting with PD-L1 expressed 
by other infiltrating immune cells, such as dendritic cells 
(DCs), rather than tumor cells. This assertion is supported 
by the results of a study of the anti-PD-L1 antibody 
atezolizumab (MPDL3280A) in multiple solid tumors, 
in which positive treatment responses were significantly 
associated with higher baseline levels of TIL-expressed 
PD-L1; in this study, there was no correlation between 
treatment response and PD-L1 expression on tumor 
cells. [70] Other studies have similarly documented 
associations between PD-L1 expression by peripheral 
blood lymphocytes, like CD4+ and CD8+ T-cells, and 
treatment response to immune checkpoint blockade [71]. 
However so far, there are no published studies evaluating 
T-cell response following treatment with checkpoint 
inhibitors in GBM.
Atypical responses have also been observed in the 
use of immune checkpoint inhibitors and must also be 
considered as well. In some cases, anti-PD therapy has 
been associated with accelerated disease progression and 
reduced OS, in a phenomenon known as hyperprogressive 
disease (HPD) [84–87]. Observed in a small subset of 
patients, HPD occurs in many different tumor types and 
has been shown to be independent of initial tumor burden. 
Although the mechanism of HPD remains unknown, 
it has been linked with several genetic changes and is 
associated with advanced patient age, raising concerns for 
PD blockade in the elderly population [84, 85].
CHECKMATE 143 TRIAL
CheckMate 143 (NCT 02017717), sponsored by 
Bristol-Myers Squibb (BMS), was the first large-scale 
randomized clinical trial of PD pathway inhibition in the 
setting of malignant glioma. It was designed to evaluate 
the safety and efficacy of nivolumab in the treatment of 
patients with GBM and included a study of nivolumab 
monotherapy as compared to bevacizumab in the setting 
of recurrent disease. Patients received either nivolumab 
3mg/kg or bevacizumab 10mg/kg IV every 2 weeks, until 
disease progression or unacceptable toxicity. At the time 
of final analysis, this phase III clinical trial enrolled 369 
patients with first recurrence of GBM, previously treated 
with combination radiation and TMZ. At baseline, a 
significant proportion of patients in both treatment arms, 
40% (nivolumab) and 43% (bevacizumab), required 
glucocorticoid therapy, with 14% (nivolumab) and 15% 
(bevacizumab) receiving ≥ 4 mg/day.
Results reported in April of 2017 at the WFNOS 
conference revealed a failure of nivolumab to extend OS in 
patients with recurrent GBM as compared to bevacizumab, 
and this arm of the trial was prematurely terminated. In 
both treatment groups, the 12-month OS was 42%. The 
median OS for patients treated with nivolumab was 9.8 
months as compared to 10 months for those receiving 
bevacizumab monotherapy. Median PFS was 1.5 months 
(nivolumab) and 3.5 months (bevacizumab). Overall 
treatment response rates were 8% (nivolumab) and 23% 
(bevacizumab) and median durations of response were 
11.1 months (nivolumab) and 5.3 months (bevacizumab). 
Treatment-related adverse events (TRAEs) occurred in 
57% (nivolumab) and 58% (bevacizumab) of patients, 
with the most common being fatigue (21% vs 14%) and 
hypertension (1% vs 22%). Grade 3–4 TRAEs occurred 
in 18% (nivolumab) and 15% (bevacizumab) of patients 
and TRAEs leading to discontinuation of therapy were 
reported in 10% (nivolumab) and 15% (bevacizumab) of 
patients [15].
BMS is currently conducting two additional trials 
of combination nivolumab and RT with or without TMZ 
in patients with newly diagnosed MGMT-unmethylated, 
CheckMate-498 (NCT02617589), and MGMT-methylated, 
CheckMate-548 (NCT02667587), GBM, both of which 
are recruiting participants.
INSIGHT INTO TRIAL FAILURE
Dependent upon interactions with PD-1-expressing 
T-cells, one possible etiology of treatment failure is 
an impairment of the interaction between nivolumab 
and PD-1 receptors on patient lymphocytes. This 
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could be related to a systemic lymphopenia, reduced 
T-cell expression of PD-1, or the presence of structural 
barriers preventing T-cell-antibody interactions (Figure 
4). Although baseline information regarding the 
immune status of patients enrolled in this trial is not 
available, it is widely known that patients suffering 
from GBM experience global immune dysfunction and 
possess reduced levels of circulating CD4+ and CD8+ 
lymphocytes, an effect compounded by lymphocyte-
depleting treatments such as chemotherapy [88, 89]. The 
treatment of CNS pathology, including malignant glioma, 
has been historically limited by poor drug penetration 
of the BBB [4], which is significantly prohibitive for 
compounds of size greater than 400-600 Da [90]. The 
calculated molecular mass of nivolumab is 146 kDa [57], 
supporting the assertion that antibody-mediated inhibition 
of the PD-1/PD-L1 axis occurs external to tumor sites and 
that effector T-cells, activated against tumor-associated 
antigens in peripheral lymphoid tissues, enter the TME 
precoated with anti-PD-1 antibodies [52]. With tumor 
progression and particularly in the setting of recurrent 
disease, any PD-1-expressing lymphocytes activated 
against tumor antigens would be expected to have already 
migrated to tumor sites, where they are inaccessible to 
monoclonal antibodies.
Upon introduction to tumor sites, effector 
T-cells are exposed to a multitude of concentrated 
immunosuppressive factors within the surrounding milieu, 
including PD-L1. As a result, antigen-specific T-cells in 
patients with GBM are heavily dysfunctional and often 
are rendered permanently anergic, or tolerogenic towards 
tumor-associated antigens. Studies of T-cell function in 
the setting of chronic antigen exposure have suggested 
that these “exhausted” T-cells expressing high levels of 
PD-1 have poor effector functions that may not be fully 
restored with PD-1 blockade [91–93]. PD-1 blockade can 
“remove the brakes” placed on host immune responses 
by PD pathway signaling at tumor sites, however the 
ultimate antitumor effect is constrained by the host’s 
ability to generate adaptive immune responses against 
tumor-associated antigens, an ability that is often 
significantly impaired in GBM. “Removing the brakes” 
from a dysfunctional, inadequate immune response leaves 
an uninhibited, though still dysfunctional and inadequate, 
immune response; thus, given the highly complex network 
of immunosuppression commonly present in GBM, single-
agent therapy with PD-1 inhibition is unlikely to address 
and alleviate all factors contributing to T-cell dysfunction, 
and therefore would not be expected to result in durable, 
sustained tumor regression.
Figure 4: In recurrent disease, efficacy of nivolumab is limited by its inability to cross the blood brain barrier and 
a paucity of functional circulating T-cells with which to interact and form a protective barrier against subsequent 
possible PD-1/PD-L1 interactions.  Exposed to numerous immunosuppressive influences within the glioma microenvironment, 
including uninhibited PD-1/PD-L1 interactions, T-cells already sequestered within the TME are expected to be heavily dysfunctional and 
unable to be rescued solely with immune checkpoint inhibition.
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FUTURE DIRECTION
Despite failing to prolong OS in patients with 
recurrent GBM, nivolumab may still have a place in the 
successful treatment of this disease. A small subset (8%) 
of patients in the CheckMate 143 trial did respond to 
nivolumab, and with a much longer duration of response 
(11.1 months) than seen with bevacizumab therapy (5.3 
months). Further analysis of this subgroup in terms of 
immune status and tumor biomarkers will provide key 
insight regarding treatment failure and pave a pathway for 
future success.
Bevacizumab, the alternative treatment to 
nivolumab in the Check Mate 143 trial, is used regularly 
in the treatment for patients with recurrent GBM and 
will likely remain a component of standard therapy. 
In both primary and recurrent GBM, bevacizumab has 
been shown to increase PFS and improve peritumoral 
edema, reducing the need for immunosuppressive 
glucocorticoids known to interfere with the efficacy of 
immunotherapy [94]. Although not shown to extend 
OS, bevacizumab may confer additional benefits in the 
setting of immunotherapy. High levels of intratumoral 
VEGF are strongly immunosuppressive, promoting the 
activity of Treg cells, shifting DC populations towards 
an immature phenotype, and inducing apoptosis in CD8+ 
T-cells, effects abrogated with the use of anti-VEGF 
therapy [95]. The vasculature-normalizing effects of 
anti-VEGF therapy have also been shown to improve 
delivery of chemotherapeutic agents to tumor sites and 
enhance intratumoral immune cell infiltration, improving 
the efficacy of therapies like adoptive T-cell transfer [95, 
96]. Furthermore, in a recent phase I trial of patients with 
metastatic melanoma, bevacizumab enhanced intratumoral 
lymphocyte infiltration and humoral immune responses 
in combination with CTLA-4 blockade [97]. Although 
bevacizumab independently has immune-modulating 
functions and can provide some synergistic effects in 
combination with nivolumab, this synergy may be further 
enhanced with the addition of other immune-modulating 
strategies.
The addition of therapies addressing other 
immunosuppressive pathways, like CTLA-4 blockade, 
is one promising treatment strategy for recurrent GBM. 
In contrast to PD-L1, which suppresses existing immune 
responses, CTLA-4 signaling inhibits initial immune cell 
activation. Combination anti-PD-1 and anti-CTLA-4 
treatment in several studies has resulted in better clinical 
outcomes than seen with either agent alone [79, 98]. 
Furthermore, CTLA-4 and PD-1 expression in peripheral 
blood and tumor-infiltrating lymphocytes increases with 
immune checkpoint inhibition, reflecting the expansion of 
effector T-cell populations that would otherwise have been 
apoptotic or dysfunctional. Additionally, this increased 
expression of immune checkpoint molecules renders 
patients more susceptible to immune checkpoint blockade 
and represents another indication for combination 
treatment [99]. Combining immune checkpoint blockade 
with other chemotherapeutic agents has also been shown 
to relieve tumor-induced immunosuppression and 
improve immune and clinical outcomes. Combination 
treatment with CT-011, an anti-PD-1 antibody, and 
cyclophosphamide resulted in a significant decrease in 
intratumoral Treg cell infiltration as well as an increase 
in the presence of antigen-specific CD8+ T-cells [100]. 
Mkrtichyan and colleagues also reported that treating mice 
with combination cyclophosphamide and a PD-1 inhibitor 
reduced the presence of exhausted PD-1-expressing 
immune cells within the TME, allowing infiltration and 
proliferation of non-exhausted, functional, PD-1-deficient 
T-cells [101].
Another strategy to augment the efficacy of 
nivolumab in patients with GBM is combination treatment 
with immunotherapies that actively stimulate immune 
responses. Radiotherapy, a component of the standard 
treatment for GBM, induces phenotypic changes in 
tumor cells that enhance their susceptibility to immune-
mediated destruction, such as increased expression of 
death receptors, costimulatory molecules, stress ligands, 
adhesion molecules, and MHC class I molecules [102]. 
RT also promotes intracellular protein degradation 
and broadens the peptide repertoire of available tumor 
antigens by inducing the production of novel proteins 
[103]. Although GBM is known to have fewer mutations 
and tumor associated antigens (TAA) compared to various 
other cancers [104], future immunostimulatory strategies 
will involve targeting predominantly tumor-generated 
neo-antigens instead of TAA. Treatment with TMZ and 
fractionated RT have specifically been shown to increase 
IFN-γ release, leading to upregulation of PD-L1 in in 
vitro GBM cell lines [105]. Tumor cell death induced 
by RT and chemotherapy releases inflammatory tumor 
cell debris and tumor-associated antigens into the TME, 
leading to increased antigen presentation and activation 
of adaptive immune responses [102, 106]. Other therapies 
to consider that promote the activation and recruitment 
of inflammatory cells to the TME include DC-based 
vaccination, oncolytic virotherapy (OVT), and adoptive 
T-cell transfer [107–109]. Tumor cell PD-L1 expression 
has been shown to preclude the effectiveness of adoptive 
T-cell therapy by promoting apoptosis of transferred cells, 
an effect that can be abrogated with the addition of PD-1 
blocking antibodies [110]. In a preclinical study of mice 
bearing B7-H1/SCCVII tumors treated with adoptive 
T-cell transfer, anti-PD-1 therapy, or both, combination 
treatment was required to achieve ultimate tumor 
regression and prolonged animal survival [108]. Given 
the mechanisms underlying PD-L1 upregulation, patients 
with stronger IFN-γ-releasing adaptive immune responses 
and more intense intra- and peritumoral inflammation 
would be expected to exhibit higher levels of PD-L1 
expression, and therefore increased susceptibility to 
Oncotarget91789www.impactjournals.com/oncotarget
anti-PD therapy. This represents another mechanism of 
synergy whereby immunotherapies that enhance IFN-γ 
secretion, such as OVT, will locally sensitize tumors 
to PD blockade [109]. In a recent study of combination 
OVT and PD blockade, an oncolytic measles virus was 
shown to upregulate expression of PD-L1 in human GBM 
cells, and combination therapy led to prolonged survival 
of C57BL/6 mice bearing syngeneic orthotopic GL261 
gliomas. Tumor analysis in treated mice revealed an 
elevated influx of inflammatory immune cells, particularly 
antigen-specific CD8+ CTLs [111]. Treatment with 
nivolumab has also been associated with activation of a 
variety of genes associated with innate immunity and IFN-
γ-releasing natural killer (NK) cell function, introducing 
the possibility of combination treatment with NK cell-
directed therapies as well [73, 98, 100].
Finally, if the mechanism of the CheckMate 
trial failure involves an inability of nivolumab to 
reach TILs already sequestered in the recurrent tumor 
microenvironment, it may be expected to function better 
in patients with newly diagnosed GBM, where newly 
activated circulating T-cells would be available for 
interaction with nivolumab prior to their migration to 
tumor sites. Additionally, surgical resection and radiation 
therapy employed in the treatment of primary disease 
provide tumor debulking leading to GBM cell death, 
elaboration of tumor-associated antigens, and the release 
of TILs into the periphery, increasing their availability for 
interaction with circulating nivolumab [112].
CONCLUSION
The use of immune checkpoint inhibitors, like 
nivolumab, has resulted in improved clinical outcomes 
for patients with a variety of cancers. In order to 
successfully extend the application of immune checkpoint 
blockade therapy to patients with GBM, future studies 
must consider the unique aspects of these tumors and 
the immune status observed in patients with primary and 
recurrent disease. An improved understanding of how the 
quantity and quality of TILs influence antitumor responses 
and PD blockade in the setting of primary vs. recurrent 
GBM, and a better analysis of the relative contributions 
of other determinants of patient responses to therapy 
will be imperative in designing an optimal treatment 
regimen. The ideal pairing of anti-PD pathway treatment 
with immunotherapies that counteract tumor-induced 
immunosuppression and/or enhance the generation of 
antitumor responses will likely confer the strongest benefit 
in immune and clinical outcomes for patients with both 
primary and recurrent GBM. The unique combination of 
these therapies will both “remove the brakes” and “step on 
the gas” of the vehicle that is the host antitumor immune 
response, working together to advance the field of glioma 
immunotherapy.
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